实用医学杂志
實用醫學雜誌
실용의학잡지
THE JOURNAL OF PRACTICAL MEDICINE
2015年
8期
1307-1310
,共4页
王轩%王欣%孙静峰%夏兵祥%袁振华%郑苏文%张业伟
王軒%王訢%孫靜峰%夏兵祥%袁振華%鄭囌文%張業偉
왕헌%왕흔%손정봉%하병상%원진화%정소문%장업위
IL-16%基因多态性%肿瘤%Meta分析
IL-16%基因多態性%腫瘤%Meta分析
IL-16%기인다태성%종류%Meta분석
目的:先探索白介素-16(IL-16)基因多态性与肿瘤易感性的关系。方法:通过计算机检索和手工检索,收集有关IL-16基因多态性与肿瘤易感性关系的文献,筛选出符合条件的文献,应用 Meta 分析软件对各项研究进行异质性检验,计算合并OR 值及其95%可信区间,并行敏感性分析和发表偏倚的评估。结果:共有6篇文献纳入本研究(肿瘤例数1678;对照例数2417), Meta 分析结果显示 IL-16与肿瘤易感性的关系:rs11556218(G vs. T:OR =1.41,95%CI 1.13~1.77;GG vs. TT:OR =1.21,95%CI 0.89~1.64;GT vs. TT:OR =1.65,95%CI 1.42~1.91;GG/GT vs. TT:OR =1.60,95%CI 1.39~1.85;GG vs. TT/TG:OR =0.93,95%CI 0.70~1.24);rs4072111(T vs. C:OR =1.00,95%CI 0.88~1.13;TT vs. CC:OR =1.04,95%CI 0.72~1.49;CT vs. CC:OR =0.97,95%CI 0.84~1.13;TT/TC vs. CC:OR =0.98,95%CI 0.85~1.14;TT vs. CC/CT:OR =1.06,95%CI 0.74~1.51);rs4778889(C vs. T:OR =1.04,95%CI 0.80~1.35;CC vs. TT:OR =0.77,95%CI 0.49~1.22;CT vs. TT:OR =0.95,95%CI 0.77~1.18;CC/CT vs. TT:OR =0.93,95%CI 0.75~1.16;CC vs. CT/TT:OR =0.75,95%CI 0.55~1.02)。通过肿瘤类型的分层分析,在 IL-16 rs11556218基因多态性中与TT相比较,GT或GG/GT能增加鼻咽癌(OR =1.74,95%CI 1.28~2.37;OR =1.73,95%CI 1.28~2.34)和结直肠癌(OR =1.86,95%CI 1.49~2.32;OR =1.76,95%CI 1.41~2.18)的风险。结论:IL-16 rs11556218基因多态性中GT或GG/GT基因型可增加患肿瘤的风险。
目的:先探索白介素-16(IL-16)基因多態性與腫瘤易感性的關繫。方法:通過計算機檢索和手工檢索,收集有關IL-16基因多態性與腫瘤易感性關繫的文獻,篩選齣符閤條件的文獻,應用 Meta 分析軟件對各項研究進行異質性檢驗,計算閤併OR 值及其95%可信區間,併行敏感性分析和髮錶偏倚的評估。結果:共有6篇文獻納入本研究(腫瘤例數1678;對照例數2417), Meta 分析結果顯示 IL-16與腫瘤易感性的關繫:rs11556218(G vs. T:OR =1.41,95%CI 1.13~1.77;GG vs. TT:OR =1.21,95%CI 0.89~1.64;GT vs. TT:OR =1.65,95%CI 1.42~1.91;GG/GT vs. TT:OR =1.60,95%CI 1.39~1.85;GG vs. TT/TG:OR =0.93,95%CI 0.70~1.24);rs4072111(T vs. C:OR =1.00,95%CI 0.88~1.13;TT vs. CC:OR =1.04,95%CI 0.72~1.49;CT vs. CC:OR =0.97,95%CI 0.84~1.13;TT/TC vs. CC:OR =0.98,95%CI 0.85~1.14;TT vs. CC/CT:OR =1.06,95%CI 0.74~1.51);rs4778889(C vs. T:OR =1.04,95%CI 0.80~1.35;CC vs. TT:OR =0.77,95%CI 0.49~1.22;CT vs. TT:OR =0.95,95%CI 0.77~1.18;CC/CT vs. TT:OR =0.93,95%CI 0.75~1.16;CC vs. CT/TT:OR =0.75,95%CI 0.55~1.02)。通過腫瘤類型的分層分析,在 IL-16 rs11556218基因多態性中與TT相比較,GT或GG/GT能增加鼻嚥癌(OR =1.74,95%CI 1.28~2.37;OR =1.73,95%CI 1.28~2.34)和結直腸癌(OR =1.86,95%CI 1.49~2.32;OR =1.76,95%CI 1.41~2.18)的風險。結論:IL-16 rs11556218基因多態性中GT或GG/GT基因型可增加患腫瘤的風險。
목적:선탐색백개소-16(IL-16)기인다태성여종류역감성적관계。방법:통과계산궤검색화수공검색,수집유관IL-16기인다태성여종류역감성관계적문헌,사선출부합조건적문헌,응용 Meta 분석연건대각항연구진행이질성검험,계산합병OR 치급기95%가신구간,병행민감성분석화발표편의적평고。결과:공유6편문헌납입본연구(종류례수1678;대조례수2417), Meta 분석결과현시 IL-16여종류역감성적관계:rs11556218(G vs. T:OR =1.41,95%CI 1.13~1.77;GG vs. TT:OR =1.21,95%CI 0.89~1.64;GT vs. TT:OR =1.65,95%CI 1.42~1.91;GG/GT vs. TT:OR =1.60,95%CI 1.39~1.85;GG vs. TT/TG:OR =0.93,95%CI 0.70~1.24);rs4072111(T vs. C:OR =1.00,95%CI 0.88~1.13;TT vs. CC:OR =1.04,95%CI 0.72~1.49;CT vs. CC:OR =0.97,95%CI 0.84~1.13;TT/TC vs. CC:OR =0.98,95%CI 0.85~1.14;TT vs. CC/CT:OR =1.06,95%CI 0.74~1.51);rs4778889(C vs. T:OR =1.04,95%CI 0.80~1.35;CC vs. TT:OR =0.77,95%CI 0.49~1.22;CT vs. TT:OR =0.95,95%CI 0.77~1.18;CC/CT vs. TT:OR =0.93,95%CI 0.75~1.16;CC vs. CT/TT:OR =0.75,95%CI 0.55~1.02)。통과종류류형적분층분석,재 IL-16 rs11556218기인다태성중여TT상비교,GT혹GG/GT능증가비인암(OR =1.74,95%CI 1.28~2.37;OR =1.73,95%CI 1.28~2.34)화결직장암(OR =1.86,95%CI 1.49~2.32;OR =1.76,95%CI 1.41~2.18)적풍험。결론:IL-16 rs11556218기인다태성중GT혹GG/GT기인형가증가환종류적풍험。